Cargando…

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension

Angiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because the activation of renin–angiotensin–aldosterone system is suggested as one possible mechanism of postmenopausal hypertension. However, there are few studies substantiating this eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Song-Yi, Joo, Seung-Jae, Shin, Mi-Seung, Kim, Changsoo, Cho, Eun Joo, Sung, Ki-Chul, Kang, Seok-Min, Kim, Dong-Soo, Lee, Seung Hwan, Hwang, Kyung-Kuk, Park, Jeong Bae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	3400
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900715/ https://www.ncbi.nlm.nih.gov/pubmed/27258507 http://dx.doi.org/10.1097/MD.0000000000003764

Ejemplares similares

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study
por: Cho, Eun Joo, et al.
Publicado: (2019)

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
por: Kim, Tae Hwan, et al.
Publicado: (2016)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

Effect of Beta Blockers and Renin–Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
por: Lee, Pil Hyung, et al.
Publicado: (2016)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

Exercise-induced hypertension is associated with angiotensin II activity and total nitric oxide
por: Kim, Chul-Hyun, et al.
Publicado: (2020)

Association of β-blocker therapy with long-term clinical outcomes in patients with coronary chronic total occlusion
por: Hwang, Jin Kyung, et al.
Publicado: (2016)

Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report
por: Park, Dae Hwa, et al.
Publicado: (2017)

Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure
por: Quan, Hailian, et al.
Publicado: (2020)

Sustained beneficial effect of β-blockers on clinical outcomes after discontinuation in patients with ST elevation myocardial infarction
por: Park, Jin-Sun, et al.
Publicado: (2023)

Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study
por: Hsieh, Yu-Cheng, et al.
Publicado: (2016)

Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension
por: Zhang, Jingsi, et al.
Publicado: (2021)

Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials
por: Zhao, Yun-Tao, et al.
Publicado: (2016)

Comparison of 2-year clinical outcomes between diabetic versus nondiabetic patients with acute myocardial infarction after 1-month stabilization: Analysis of the prospective registry of DIAMOND (DIabetic acute myocardial infarctiON Disease) in Korea: an observational registry study
por: Hur, Seung-Ho, et al.
Publicado: (2016)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

The impact of educational attainment on cardiorespiratory fitness and metabolic syndrome in Korean adults
por: Chang, Mineok, et al.
Publicado: (2020)

Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: K-MetS Study
por: Cho, Jaelim, et al.
Publicado: (2016)

Relationship between arterial stiffness and variability of home blood pressure monitoring
por: Park, Jin-Sun, et al.
Publicado: (2020)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis
por: lv, Xiaodan, et al.
Publicado: (2018)

CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents
por: Choi, Ik Jun, et al.
Publicado: (2016)

Short stature is associated with higher pulse wave velocity in subjects without overt cardiovascular disease
por: Moon, Jeonggeun, et al.
Publicado: (2020)

Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study
por: Oh, Gyu Chul, et al.
Publicado: (2020)

Off-label use of an iliac branch device and a reversed iliac limb for a patient with a unilateral common iliac artery aneurysm and a narrow distal aorta: A case report
por: Hwang, Deokbi, et al.
Publicado: (2023)

Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
por: Lee, Jae-Geun, et al.
Publicado: (2023)

Prediction of early-onset atrial tachyarrhythmia after successful trans-catheter device closure of atrial septal defect
por: Park, Kyoung-Min, et al.
Publicado: (2016)

Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2
por: Kim, Soojeong, et al.
Publicado: (2015)

Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer
por: Seo, Kyoung-Woo, et al.
Publicado: (2021)

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study): An Open-Label Observational Study
por: Park, Jeong Bae, et al.
Publicado: (2013)

Exercise-induced hypertension can increase the prevalence of coronary artery plaque among middle-aged male marathon runners
por: Kim, Chul-Hyun, et al.
Publicado: (2020)

Prognostic impact of left ventricular mass change in patients with ST-elevation myocardial infarction
por: Park, Jin-Sun, et al.
Publicado: (2018)

Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Patients Following Ablation of Atrial Fibrillation
por: Park, Jeong-Hwan, et al.
Publicado: (2009)

Diagnostic value of the corrected QT difference between leads V1 and V6 in patients with acute pulmonary thromboembolism
por: Park, Seong Jun, et al.
Publicado: (2017)

The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics
por: Kim, Changsoo, et al.
Publicado: (2014)

Pacemaker dependency after transcatheter aortic valve replacement compared to surgical aortic valve replacement
por: Hwang, You Mi, et al.
Publicado: (2021)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
por: Choi, Jin Sun, et al.
Publicado: (2023)

Predictors and long-term clinical outcomes of newly developed atrial fibrillation in patients with cardiac implantable electronic devices
por: Kim, Bum Sung, et al.
Publicado: (2016)

The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article)
por: Hyun, Myung Han, et al.
Publicado: (2019)

Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
por: Kim, Inho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eriuqcdkkogc7luv3lb2pln3i5